Acadia Pharmaceuticals (ACAD) Total Current Liabilities (2010 - 2026)

Acadia Pharmaceuticals' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $305.5 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 0.99% year-over-year to $305.5 million; the TTM figure through Mar 2026 stood at $305.5 million (up 0.99% YoY), while the FY2025 annual figure was $277.1 million, down 29.82% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $305.5 million, up from $277.1 million in the prior quarter.
• The five-year high for Total Current Liabilities was $394.9 million in Q4 2024, with the low at $116.6 million in Q3 2022.
• The 5-year median for Total Current Liabilities is $277.1 million (2025), against an average of $255.0 million.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities jumped 102.38% in 2023, then dropped 29.82% in 2025.
• Acadia Pharmaceuticals' Total Current Liabilities stood at $125.6 million in 2022, then surged by 102.38% to $254.3 million in 2023, then jumped by 55.31% to $394.9 million in 2024, then decreased by 29.82% to $277.1 million in 2025, then rose by 10.25% to $305.5 million in 2026.
• Business Quant data shows ACAD's Total Current Liabilities at $305.5 million in Q1 2026, $277.1 million in Q4 2025, and $356.6 million in Q3 2025.